Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system

Cazarim, Maurílio de Souza; Rodrigues, Josemar; Cruz-Cazarim, Estael Luzia Coelho da; Ayres, Lorena Rocha; Pereira, Leonardo Régis Leira

doi:10.1590/s2175-97902017000300178

Cited by 2 publications

(1 citation statement)

References 15 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our hospital is a public hospital that is part of the Brazilian national unified public health system (Sistema Único de Saúde -SUS) (17), in which human insulins (NPH and regular) are the standard treatment defined by the Brazilian Ministry of Health (30). Pharmacoeconomic studies that evaluated human insulins and insulin analogues have suggested that the use of human insulins are the best options in relation to the cost of treatment (31,32). However, the majority of inpatient insulin therapy studies have been performed with insulin analogues.…”

Section: Discussionmentioning

confidence: 99%

InsulinAPP application protocol for the inpatient management of type 2 diabetes on a hospitalist-managed ward: a retrospective study

Toyoshima¹,

Brandes²,

Lauterbach³

et al. 2022

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective:We assessed metrics related to inpatient glycemic control using InsulinAPP, an application available for free in Brazil, on the hospitalist-managed ward of our hospital. Subjects and methods: We performed a retrospective study of patients with type 2 diabetes (T2D) admitted from November 2018 to October 2019. InsulinAPP recommends NPH and regular insulins three times a day, in boluscorrection or basal-bolus schemes. Parameters that included BG within range of 70-180 mg/dL, insulin treatment regimen and frequency of hypoglycemia were evaluated. Results: A total of 147 T2D individuals (23% medicine and 77% surgery) were included (mean age 62.3 ± 12.7 years, HbA1c: 8.3 ± 3.0%). The initial insulin regimen was 50% bolus-correction, 47% basal-bolus and 3% with sliding scale insulin. During hospitalization, 71% patients required a bolus-basal regimen. In the first 10 days of the protocol, 71% BG measurements were between 70-180 mg/dL and 26% patients experienced one or more episodes of hypoglycemia < 70 mg/dL, and 5% with BG < 54 mg/dL. Conclusion: The results of this retrospective study indicate the InsulinAPP application using human insulin formulations was effective and safe for the management of hyperglycemia on a hospitalist-managed ward, with more than 70% BG measurements within the therapeutic range and a low rate of hypoglycemia.

show abstract

Section: Discussionmentioning

confidence: 99%